Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression

Hepatology Research : the Official Journal of the Japan Society of Hepatology
H KumadaK Chayama

Abstract

To assess the efficacy and safety of telaprevir (TVR) when used in combination with natural human interferon-β (IFN-β) and ribavirin (RBV) for genotype 1 patients with depression compared to IFN-β/RBV therapy in Japan. We also examined the efficacy of the TVR/IFN-β/RBV therapy in treatment failure genotype 2 patients with depression. For the genotype 1 patients, 30 patients received TVR (750 mg every 8 h) for 12 weeks combined with IFN-β and RBV for 24 weeks (Group A), and 30 received IFN-β and RBV for 48 weeks (Group B). For the genotype 2 patients, 14 patients were dosed only with the TVR-based regimen. The sustained virologic response (SVR) rates for Group A and Group B were 63.3% and 20.0%, respectively (P = 0.001, likelihood ratio test). The SVR rate for genotype 2 patients previously treated with pegylated IFN and/or RBV was 71.4%. No patient dropped out due to exacerbation of depression. The trend of platelet counts after the drugs were given was similar in the TVR/IFN-β/RBV therapy group and the IFN-β/RBV therapy group. Common resistance-associated variants of TVR were identified in 4 of the 13 patients who did not achieve SVR. This study showed that an addition of TVR to IFN-β/RBV therapy raised SVR in previously treat...Continue Reading

References

Aug 15, 2001·Journal of Human Genetics·Y OhnishiY Nakamura
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Sep 16, 2009·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Sanjeev Sockalingam, Susan E Abbey
Jan 14, 2010·Intervirology·Hobyung ChungMasatoshi Kudo
Dec 20, 2011·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hideyuki NomuraSaburo Nishiura
May 23, 2012·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yasuji AraseHiromitsu Kumada
Jul 11, 2012·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yasuji AraseHiromitsu Kumada
Mar 8, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hiromitsu KumadaEric Hughes
Jul 9, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Koji TakayamaJun Hayashi
Sep 10, 2014·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hiromitsu KumadaTakeshi Okanoue
Feb 4, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kazuaki ChayamaHiromitsu Kumada
Feb 7, 2015·Journal of Medical Virology·Norio AkutaHiromitsu Kumada
Jul 7, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hiromitsu KumadaRebecca Redman
Feb 16, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yasuhiro AsahinaHiroshi Yotsuyanagi
Apr 12, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hiromitsu KumadaIchimaro Yamada

❮ Previous
Next ❯

Citations

Feb 23, 2021·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Razan SakranDaniel Kurnik

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.